Accès gratuit
Numéro
Med Sci (Paris)
Volume 27, Numéro 6-7, Juin–Juillet 2011
Page(s) 619 - 625
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2011276014
Publié en ligne 1 juillet 2011
  1. Wu JT, Kral JG. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Surg Res 2005 ; 123 : 158-169. [CrossRef] [PubMed]
  2. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008 ; 132 : 344-362. [CrossRef] [PubMed]
  3. Clement JF, Meloche S, Servant MJ. The IKK-related kinases: from innate immunity to oncogenesis. Cell Res 2008 ; 18 : 889-899. [CrossRef] [PubMed]
  4. Shimada T, Kawai T, Takeda K, et al. IKK-i, a novel lipopolysaccharide-inducible kinase that is related to IkappaB kinases. Int Immunol 1999 ; 11 : 1357-1362. [CrossRef] [PubMed]
  5. Peters RT, Liao SM, Maniatis T. IKKepsilon is part of a novel PMA-inducible IkappaB kinase complex. Mol Cell 2000 ; 5 : 513-522. [CrossRef] [PubMed]
  6. Kishore N, Huynh QK, Mathialagan S, et al. IKK-i and TBK-1 are enzymatically distinct from the homologous enzyme IKK-2: comparative analysis of recombinant human IKK-i, TBK-1, and IKK-2. J Biol Chem 2002 ; 277 : 13840-13847. [CrossRef] [PubMed]
  7. Kravchenko VV, Mathison JC, Schwamborn K, et al. IKKi/IKKepsilon plays a key role in integrating signals induced by pro-inflammatory stimuli. J Biol Chem 2003 ; 278 : 26612-26619. [CrossRef] [PubMed]
  8. Tenoever BR, Ng SL, Chua MA, et al. Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science 2007 ; 315 : 1274-1278. [CrossRef] [PubMed]
  9. Sweeney SE, Hammaker D, Boyle DL, Firestein GS. Regulation of c-Jun phosphorylation by the IkappaB kinase-epsilon complex in fibroblast-like synoviocytes. J Immunol 2005 ; 174 : 6424-6430. [PubMed]
  10. Wang N, Ahmed S, Haqqi TM. Genomic structure and functional characterization of the promoter region of human IkappaB kinase-related kinase IKKi/IKKvarepsilon gene. Gene 2005 ; 353 : 118-133. [CrossRef] [PubMed]
  11. Hutti JE, Shen RR, Abbott DW, et al. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell 2009 ; 34 : 461-472. [CrossRef] [PubMed]
  12. Guo JP, Shu SK, Esposito NN, et al. IKKepsilon phosphorylation of estrogen receptor alpha Ser-167 and contribution to tamoxifen resistance in breast cancer. J Biol Chem 2010 ; 285 : 3676-3684. [CrossRef] [PubMed]
  13. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009 ; 693-733. [CrossRef] [PubMed]
  14. Perry AK, Chow EK, Goodnough JB, et al. Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infection. J Exp Med 2004 ; 199 : 1651-1658. [CrossRef] [PubMed]
  15. Hemmi H, Takeuchi O, Sato S, et al. The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J Exp Med 2004 ; 199 : 1641-1650. [CrossRef] [PubMed]
  16. Boehm JS, Zhao JJ, Yao J, et al. Integrative genomic approaches identify IKBKε as a breast cancer oncogene. Cell 2007 ; 129 : 1065-1079. [CrossRef] [PubMed]
  17. Eddy SF, Guo S, Demicco EG, et al. Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells. Cancer Res 2005 ; 65 : 11375-11383. [CrossRef] [PubMed]
  18. Nomura F, Kawai T, Nakanishi K, Akira S. NF-kappaB activation through IKK-i-dependent I-TRAF/TANK phosphorylation. Genes Cells 2000 ; 5 : 191-202. [CrossRef] [PubMed]
  19. Adli M, Baldwin AS. IKK-i/IKKepsilon controls constitutive, cancer cell-associated NF-kappaB activity via regulation of Ser-536 p65/RelA phosphorylation. J Biol Chem 2006 ; 281 : 26976-26984. [CrossRef] [PubMed]
  20. Mattioli I, Geng H, Sebald A, et al. Inducible phosphorylation of NF-kappaB p65 at serine 468 by T cell costimulation is mediated by IKK epsilon. J Biol Chem 2006 ; 281 : 6175-6183. [CrossRef] [PubMed]
  21. Harris J, Oliere S, Sharma S, et al. Nuclear accumulation of cRel following C-terminal phosphorylation by TBK1/IKKepsilon. J Immunol 2006 ; 177 : 2527-2535. [PubMed]
  22. Sharma S, tenOever BR, Grandvaux N, et al. Triggering the interferon antiviral response through an IKK-related pathway. Science 2003 ; 300 : 1148-1151. [CrossRef] [PubMed]
  23. Fitzgerald KA, McWhirter SM, Faia KL, et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 2003 ; 4 : 491-496. [CrossRef] [PubMed]
  24. Huang W, Ghisletti S, Perissi V, et al. Transcriptional integration of TLR2 and TLR4 signaling at the NCoR derepression checkpoint. Mol Cell 2009 ; 35 : 48-57. [CrossRef] [PubMed]
  25. Seo SI, Song SY, Kang MR, et al. . Immunohistochemical analysis of NF-kappaB signaling proteins IKKepsilon, p50/p105, p52/p100 and RelA in prostate cancers. Apmis 2009 ; 117 : 623-628. [CrossRef] [PubMed]
  26. Guo JP, Shu SK, He L, et al. Deregulation of IKBKε is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer. Am J Pathol 2009 ; 175 : 324-333. [CrossRef] [PubMed]
  27. Sovak MA, Bellas RE, Kim DW, et al. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997 ; 100 : 2952-2960. [CrossRef] [PubMed]
  28. Romieu-Mourez R, Kim DW, Shin SM, et al. Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol Cell Biol 2003 ; 23 : 5738-5754. [CrossRef] [PubMed]
  29. Sun SC. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ 2010 ; 17 : 25-34. [CrossRef] [PubMed]
  30. Zhang M, Wu X, Lee AJ, et al. Regulation of IkappaB kinase-related kinases and antiviral responses by tumor suppressor CYLD. J Biol Chem 2008 ; 283 : 18621-18626. [CrossRef] [PubMed]
  31. Barone I, Brusco L, Fuqua SA. Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res 2010 ; 16 : 2702-2708. [CrossRef] [PubMed]
  32. Lee DF, Hung MC. Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin Cancer Res 2008 ; 14 : 5656-5662. [CrossRef] [PubMed]
  33. Clark K, Plater L, Peggie M, Cohen P. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. J Biol Chem 2009 ; 284 : 14136-14146. [CrossRef] [PubMed]
  34. Baud V, Jacque E. The alternative NF-κB activation pathway and cancer: friend or foe?. Med Sci (Paris) 2008 ; 24 : 1083-1088. [CrossRef] [EDP Sciences] [PubMed]
  35. Gautheron J, Courtois G. New functions of NEMO, the regulatory subunit of IKK. Med Sci (Paris) 2008 ; 24 : 954-959. [CrossRef] [EDP Sciences] [PubMed]
  36. Bonnet M, Courtois G. La déubiquitinase CYLD : une cible recurrente dans les processus oncogéniques. Med Sci (Paris) 2011 ; 27 : 626-631. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.